Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company focused on hard-to-treat cancers, announced strategic appointments to its Board of Directors and corporate secretary position, effective immediately. The moves are part of the company's broader capital markets strategy, including preparations for a planned listing on the Nasdaq through the Multijurisdictional Disclosure System (MJDS).
Zachary T. Stadnyk, a former TSX Life Sciences Lead with over 15 years of experience in biotechnology capital markets and public company leadership, has been appointed to the Board. Stadnyk previously served as Head of Life Sciences at the TSX and TSXV, advising biotech issuers and institutional investors on public listings and capital formation. He has led and supported over $100 million in institutional financings and contributed to strategic transactions, including the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth. Natalia L. Butterworth, Director, Corporate Secretarial and Governance at ARO Consulting Inc., has been appointed Corporate Secretary. Butterworth brings over 15 years of governance and regulatory compliance experience across pharmaceutical, technology, and finance sectors.
"As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority," said Thomas Mehrling, MD, PhD, CEO of Helix BioPharma. "These appointments come at an important time for Helix as we finalize the clinical protocol for L-DOS47 and actively prepare for a Nasdaq listing under the MJDS, including ongoing audit, governance, and capital markets readiness initiatives."
Stadnyk added, "I am excited to join Helix at such a pivotal stage in its development. The Company’s differentiated approach to addressing the tumor microenvironment and its clear path toward a Nasdaq listing creates a compelling opportunity."
In conjunction with these appointments, Helix is in the process of relocating its registered and records office from Toronto, Ontario to Vancouver, British Columbia. The move aligns with the strengthening of the company's governance and capital markets infrastructure as it advances its Nasdaq uplisting strategy under the MJDS framework.
Helix's pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC). The company also advances two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator, and GEMCEDA, an oral gemcitabine prodrug.
These appointments signal Helix's commitment to enhancing its capital markets expertise and governance as it moves toward a major milestone—a Nasdaq listing. For investors, this could potentially increase the company's visibility and access to a broader investor base, while the strengthened board may help navigate the complexities of clinical development and regulatory pathways.
More information about Helix BioPharma is available at https://www.helixbiopharma.com/.
